Crinetics Pharmaceuticals (CRNX)
(Real Time Quote from BATS)
$52.34 USD
-0.19 (-0.36%)
Updated Aug 16, 2024 11:02 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Crinetics Pharmaceuticals, Inc. [CRNX]
Reports for Purchase
Showing records 21 - 40 ( 88 total )
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Resizing for PATHFNDR-2 Bodes Well for Paltusotine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Crinetics Lines Up Multiple Data Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Just Bump in the Road for Crinetics? CRN04777; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
PATHFNDR 1 Finds Its Way to Enrollment Completion
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pipeline Continues to Broaden with CRN04777 Headed for Phase 2, We Expect CRN04894 to Soon Follow; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rx for Portfolios, Part 1: Companies With Transformative Clinical Readouts Fast Approaching
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
A Busy Few Months Marked by Readouts and Pipeline Expansions; Reit Buy PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Crinetics Unveils and Spins Out Non-Peptide Targeted Radiopharmaceutical Oncology Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Parathyroid Hormone Receptor Antagonist Program Broadens the Portfolio Further; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Another Win for Crinetics as CRN04777 Shows PK Proof of Concept in Phase1; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
CRN04894 Shows Pharmacodynamic Proof of Concept in First in Man Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Our Market Model for Congenital Hyperinsulinism; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Crinetics Lays the Groundwork for Paltusotine?s Path to the Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Crinetics Charts a Path to Filing for Paltusotine with PATHFNDR Registrational Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D